日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis

一项针对亚洲新诊断急性髓系白血病患者的吉瑞替尼联合化疗的I/II期研究:最终分析

Sawa, Masashi; Miyamoto, Toshihiro; Kim, Hee-Je; Hiramatsu, Yasushi; Cheong, June-Won; Ikezoe, Takayuki; Naoe, Tomoki; Akashi, Koichi; Morita, Satoshi; Kosako, Masanori; Shimura, Masaki; Terada, Wataru; Kadokura, Takeshi; Hill, Jason; Miyawaki, Shuichi; Gill, Stanley C; Heinloth, Alexandra; Hasabou, Nahla

Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial

COMMODORE III期试验中,主要为亚洲复发/难治性FLT3突变急性髓系白血病患者的长期随访

Jiang, Bin; Li, Jian; Liu, Ligen; Du, Xin; Jiang, Hao; Hu, Jianda; Zeng, Xiaoxi; Sakatani, Taishi; Kosako, Masanori; Deng, Yaru; Ivanov, Vladimir; Bondarenko, Sergey; Lee Lee, Lily Wong; Khuhapinant, Archrob; Martynova, Elena; Hasabou, Nahla; An, Jamie Jung-Hee; Wang, Jianxiang

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

对于FLT3-ITD突变型急性髓系白血病患者,可测量的残留病灶和移植后吉瑞替尼维持治疗。

Levis, Mark J; Hamadani, Mehdi; Logan, Brent R; Jones, Richard J; Singh, Anurag K; Litzow, Mark R; Wingard, John R; Papadopoulos, Esperanza B; Perl, Alexander E; Soiffer, Robert J; Ustun, Celalettin; Oshima, Masumi Ueda; Uy, Geoffrey L; Waller, Edmund K; Vasu, Sumithira; Solh, Melhem; Mishra, Asmita; Muffly, Lori S; Kim, Hee-Je; Stelljes, Matthias; Najima, Yuho; Onozawa, Masahiro; Thomson, Kirsty; Nagler, Arnon; Wei, Andrew H; Marcucci, Guido; Chen, Caroline; Hasabou, Nahla; Rosales, Matt; Hill, Jason; Gill, Stanley C; Nuthethi, Rishita; King, Denise; Mendizabal, Adam; Devine, Steven M; Horowitz, Mary M; Chen, Yi-Bin

Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia

移植预处理、NPM1突变和可测量残留病灶对FLT3-ITD急性髓系白血病的影响

Levis, Mark J; Hamadani, Mehdi; Logan, Brent R; Jones, Richard J; Singh, Anurag K; Litzow, Mark R; Wingard, John R; Papadopoulos, Esperanza B; Perl, Alexander E; Soiffer, Robert J; Ustun, Celalettin; Oshima, Masumi Ueda; Uy, Geoffrey L; Waller, Edmund K; Vasu, Sumithira; Solh, Melhem; Mishra, Asmita; Muffly, Lori S; Kim, Hee-Je; Stelljes, Matthias; Najima, Yuho; Onozawa, Masahiro; Thomson, Kirsty; Chen, Caroline; Hasabou, Nahla; Rosales, Matt; Hill, Jason E; Gill, Stanley C; Nuthethi, Rishita; King, Denise; Mendizabal, Adam; Devine, Steven M; Horowitz, Mary M; Chen, Yi-Bin

Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study

在FMS样酪氨酸激酶3内部串联重复突变型急性髓系白血病患者中,使用FMS样酪氨酸激酶3抑制剂吉瑞替尼进行维持治疗:一项II期研究

Gyan, Emmanuel; Minden, Mark D; Kubo, Kohmei; Rambaldi, Alessandro; Juliusson, Gunnar; Jädersten, Martin; Kelly, Richard J; Szerafin, László; He, Wensheng; Gill, Stanley C; Hill, Jason E; Chen, Caroline; Delgado, David; Hasabou, Nahla

Gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of COMMODORE in China, South-East Asia, and Russia

吉瑞替尼与挽救性化疗治疗复发/难治性FLT3突变急性髓系白血病(主要为亚洲患者):COMMODORE研究在中国、东南亚和俄罗斯的区域分析

Jiang, Bin; Li, Jian; Liu, Ligen; Du, Xin; Jiang, Hao; Hu, Jianda; Zeng, Xiaoxi; Sakatani, Taishi; Kosako, Masanori; Deng, Yaru; Girshova, Larisa; Bondarenko, Sergey; Lee, Lily Wong Lee; Khuhapinant, Archrob; Martynova, Elena; Hasabou, Nahla; Wang, Jianxiang

A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia

一项在亚洲开展的针对新诊断急性髓系白血病患者的吉瑞替尼联合化疗的1/2期临床研究

Sawa, Masashi; Miyamoto, Toshihiro; Kim, Hee-Je; Hiramatsu, Yasushi; Cheong, June-Won; Ikezoe, Takayuki; Naoe, Tomoki; Akashi, Koichi; Morita, Satoshi; Kosako, Masanori; Ikegaya, Moyu; Terada, Wataru; Kadokura, Takeshi; Hill, Jason; Miyawaki, Shuichi; Gill, Stanley C; Heinloth, Alexandra; Hasabou, Nahla

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3

吉瑞替尼用于FLT3内部串联重复突变型急性髓系白血病移植后维持治疗

Levis, Mark J; Hamadani, Mehdi; Logan, Brent; Jones, Richard J; Singh, Anurag K; Litzow, Mark; Wingard, John R; Papadopoulos, Esperanza B; Perl, Alexander E; Soiffer, Robert J; Ustun, Celalettin; Ueda Oshima, Masumi; Uy, Geoffrey L; Waller, Edmund K; Vasu, Sumithra; Solh, Melhem; Mishra, Asmita; Muffly, Lori; Kim, Hee-Je; Mikesch, Jan-Henrik; Najima, Yuho; Onozawa, Masahiro; Thomson, Kirsty; Nagler, Arnon; Wei, Andrew H; Marcucci, Guido; Geller, Nancy L; Hasabou, Nahla; Delgado, David; Rosales, Matt; Hill, Jason; Gill, Stanley C; Nuthethi, Rishita; King, Denise; Wittsack, Heather; Mendizabal, Adam; Devine, Steven M; Horowitz, Mary M; Chen, Yi-Bin

Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia

吉瑞替尼与安慰剂治疗FLT3-ITD阳性急性髓系白血病移植后患者的健康相关生活质量

Hamilton, Betty K; Pandya, Bhavik J; Ivanescu, Cristina; Elsouda, Dina; Hamadani, Mehdi; Chen, Yi-Bin; Levis, Mark J; Ueda Oshima, Masumi; Litzow, Mark R; Soiffer, Robert J; Ustun, Celalettin; Perl, Alexander E; Singh, Anurag K; Geller, Nancy; Hasabou, Nahla; Rosales, Matt; Cella, David; Corredoira, Laura; Pestana, Carolina; Horowitz, Mary M; Logan, Brent

Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy

在吉瑞替尼与挽救性化疗的 III 期 ADMIRAL 试验中,接受移植的 FLT3 突变复发/难治性急性髓系白血病患者的预后

Perl, Alexander E; Larson, Richard A; Podoltsev, Nikolai A; Strickland, Stephen; Wang, Eunice S; Atallah, Ehab; Schiller, Gary J; Martinelli, Giovanni; Neubauer, Andreas; Sierra, Jorge; Montesinos, Pau; Recher, Christian; Yoon, Sung-Soo; Maeda, Yoshinobu; Hosono, Naoko; Onozawa, Masahiro; Kato, Takayasu; Kim, Hee-Je; Hasabou, Nahla; Nuthethi, Rishita; Tiu, Ramon; Levis, Mark J